We all tend to take our good health for granted until something happens which makes us realize how blessed we are to have it in the first place.
It got to the point that she was living with the reality that she could be struck down with a new symptom at any moment with no prior warning.
Andreas Met, COO, Compliance and Director at Halo Labs highlights how the use of medical cannabis is on the rise in the UK and could offer relief to many NHS patients
First State Compassion, Delaware’s medical marijuana pioneer, paved the way for a robust and sustainable Delaware industry that set the bar as a model for the country.
On 1st November 2018, the UK’s Home Secretary announced changes to the scheduling of cannabis under the Misuse of Drugs Act of 2001.
Following a consultation last year, the irrefutable support for medicinal cannabis expansion on the Isle of Man is spurring the government to improve access for patients on the island. We spoke to the Minister for Health and Social Care, David Ashford, about the issue.
As the UK Government tries desperately to salvage a shattered economy, an unlikely but profitable lifeline presents itself as the medical cannabis industry booms.
Medical cannabis, namely cannabis-based products for medicinal use in humans (CBPMs), has been moved from Schedule 1 to Schedule 2 under the Misuse of Drugs Regulation 20011 in November 2018 following a very effective publicity campaign about two children with severe epilepsy.
In recent years, a number of cannabis-derived medicines, including both synthetic, and phytocannabinoids have been investigated for their potential in treating symptoms associated with Multiple Sclerosis (MS).
Medical cannabis patients experience an increase in various measures of life quality, according to a recent cross-sectional study published in the Cannabis and Cannabinoids Research journal. The study assessed web-based survey responses from over 1200 participants in the USA between April 2016 and February 2018.